A publication in CNS Drugs based on analyses included in ICER’s report: Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis
A publication in CNS Drugs based on analyses included in ICER’s report: Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis